Literature DB >> 12048523

[Primary signet ring cell carcinoma of the eccrine sweat gland in the eyelid. Immunohistochemical and ultrastructural study of a case].

F Betis FB1, V Hofman, J Lagier, P Gastaud, J Santini, P Hofman.   

Abstract

We report a case of a 45-year-old woman who exhibited a primitive eccrine sweat gland carcinoma of the eyelid. Histological study showed cellular proliferation with an Indian file pattern and some signet ring cells with sialomucin secretion. Immunohistochemical study demonstrated these cells to be positive with the anticytokeratin, anti-EMA, anti-HMFG, antiestrogen receptor and antiprogesterone receptor antibodies. Ultrastructural study showed intracytoplasmic vacuoles with numerous microvilli at the apical side. Differential diagnosis with a metastasis from a mammary adenocarcinoma is difficult and a complete staging is necessary to confirm the primitive origin of the tumor. The behavior of this tumor is marked by locoregional recurrence.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12048523

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  3 in total

Review 1.  Role of mucins in the skin during benign and malignant conditions.

Authors:  Subhankar Chakraborty; Neelima Bonthu; Benjamin J Swanson; Surinder K Batra
Journal:  Cancer Lett       Date:  2010-12-13       Impact factor: 8.679

2.  Application of the AJCC 7th edition carcinoma of the eyelid staging system: a medical center pathology based, 15-year review.

Authors:  Courtney Crawford; Colby Fernelius; Paula Young; Stephen Groo; Darryl Ainbinder
Journal:  Clin Ophthalmol       Date:  2011-11-18

3.  Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations in CDH1 and Other Clinically Actionable Mutations Imply Early Use of Targeted Agents.

Authors:  Lei-Chi Wang; Tai-Chi Lin; Yi-Chen Yeh; Hsiang-Ling Ho; Chieh-Chih Tsai; Teh-Ying Chou
Journal:  Curr Oncol       Date:  2021-02-16       Impact factor: 3.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.